相关实验视频

Updated: Apr 30, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

针对ApoE的CpG纳米免疫辅助剂改善了小鼠的阿尔茨海默氏症样病理

Xin Huang¹, Yan-Yun Sun², Yi-Ren Qin³

¹Department of General Practice, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu 215004, China; Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow University, Suzhou, Jiangsu 215123, China; Department of Neurology and Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China; MOE Key Laboratory of Geriatric Diseases and Immunology, Soochow University, Suzhou, Jiangsu 215004, China.

Journal of controlled release : official journal of the Controlled Release Society

|February 6, 2026

概括

使用新型纳米载体 (tNCpG) 向激活托尔类受体9 (TLR9),有效地通过血脑屏障传递治疗剂,显著改善老鼠阿尔茨海默病 (AD) 病理和认知功能.

科学领域:

神经科学是一个神经科学.
免疫学免疫学免疫学
纳米技术纳米技术

背景情况:

收费类受体9 (TLR9) 是阿尔茨海默病 (AD) 的潜在治疗点,通过微质和神经元激活提供神经保护.
目前的TLR9激动剂 (CpG寡氧核酸) 在穿越血脑屏障 (BBB) 时面临挑战.

研究的目的:

开发一种针对大脑的纳米载体系统,用于输送CpG寡氧核酸 (ODN),以激活中枢神经系统 (CNS) 中的TLR9.
在AD小鼠模型中评估这种向输送系统的治疗疗效.

主要方法:

开发阿波利波蛋白E (ApoE) 功能化的聚合体纳米载体 (tNCpG),用于针对性地向大脑输送CpG ODN.
静脉注射tNCpG给APP/PS1转基因小鼠3个月,从4个月开始.
评估大脑传递,微质和神经元向,Aβ斑块动态,BBB完整性,神经炎症,神经退行以及认知功能.

主要成果:

tNCpG证明了有效的脑部传递和微质和神经元的特定向.
治疗导致Aβ斑块的微质细胞增强,抑制了Aβ的产生,并促进了Aβ降解.
tNCpG改善了BBB完整性,增加了Aβ流量,减少了大脑Aβ负担,神经炎症和神经退行,拯救了认知缺陷.

结论:

使用tNCpG的向TLR9激活是克服AD治疗中BBB限制的可行策略.
这种方法有效地改善了AD病理,并在临床前小鼠模型中恢复认知功能.
tNCpG代表了阿尔茨海默病的有希望的疾病修饰治疗策略.

关键词:

阿尔茨海默病的疾病阿尔茨海默病的疾病.亚博体育在线娱乐亚博体育在线娱乐在CpG中使用.微质细胞中的微质细胞神经退行性疾病是一种神经退行性疾病.

更多相关视频

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...